Citation Impact
Citing Papers
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
2018 Standout
Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction
1988
Binding of tissue plasminogen activator to human umbilical vein endothelial cells
1987
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors
1992
Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS)
1992
Thrombolysis for pulmonary embolism
1991
TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION
1988
Why Don't Physicians Follow Clinical Practice Guidelines?
1999 Standout
Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis
1992
Anisoylated Plasminogen Streptokinase Activator Complex (APSAC)
1987
Bleeding during Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management
1989
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Long-term follow-up of patients treated with coronary angioplasty for acute myocardial infarction
1989
Intraarterial Catheter-Directed Thrombolysis: Urokinase Versus Tissue Plasminogen Activator
1999
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy
1993
The Use of Contrast-Enhanced Magnetic Resonance Imaging to Identify Reversible Myocardial Dysfunction
2000 Standout
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial
1992
Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
1989
Antithrombotic Therapy for VTE Disease
2016 Standout
Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis
1990
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
Checking consistency in mixed treatment comparison meta‐analysis
2010 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: Results from TIMI II
1992
Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction
1989
Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
1988
GISSI-2 and the heparin controversy
1990
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction
1995
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction
1991
Thrombolytic Therapy: Current Status
1988
Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Controlled comparison with intracoronary streptokinase
1988
Which thrombolytic agent should one choose?
1991
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: Influence of infarct location on arterial patency, left ventricular function and mortality
1989
Value of gadolinium-diethylene-triamine pentaacetic acid dynamics in magnetic resonance imaging of acute myocardial infarction with occluded and reperfused coronary arteries after thrombolysis
1990
Enzymatische Marker der Reperfusion bei akutem Myokardinfarkt
1999
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
The Human Plasma Proteome
2002 Standout
A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism
1990
Human plasma fibrinogen measurement derived from activated partial thromboplastin time clot formation
2002
Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four german multicenter studies
1993
Protein therapeutics: a summary and pharmacological classification
2007 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
A Randomized Trial of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction with Subsequent Randomization to Elective Coronary Angioplasty
1987
Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism
2002 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2004 Standout
Identification and entry of the patient with acute cerebral infarction
1988
Bias in meta-analysis detected by a simple, graphical test
1997 Standout
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year
1995 Standout
Guidelines for the Early Management of Adults With Ischemic Stroke
2007 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Plasminogen activator inhibitors
1987
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
1998 Standout
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
1994 Standout
Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial Infarction
1987
Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.
1990
Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group.
1991
Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials.
1990
A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
1987
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.
1990 Standout
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.
1987 Standout
Tissue Plasminogen Activator for Acute Ischemic Stroke
1995 Standout
Air Pollution and Cardiovascular Disease
2004 Standout
A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
1991
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
1987 Standout
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis
1991
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.
1988
Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.
1992
TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study.
1993
PERMEABILITY OF MUSCLE CAPILLARIES TO EXOGENOUS MYOGLOBIN
1973 StandoutNobel
Comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity
1986
Coronary thrombolysis--clinical guidelines and public policy: results of an Ontario practitioner survey.
1990
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
1997 Standout
Critical Analysis of Coronary Artery Bypass Graft Surgery: A 30-Year Journey
1998
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
1990
Rapid Lysis of Coronary Artery Thrombi with Anisoylated Plasminogen: Streptokinase Activator Complex
1986
Relationship of MRI Delayed Contrast Enhancement to Irreversible Injury, Infarct Age, and Contractile Function
1999 Standout
THROMBOLYSIS: AN EFFECTIVE THERAPY IN ACUTE CORONARY THROMBOSIS
1986
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
1995 Standout
THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY
1988
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
The Risk of Determining Risk with Multivariable Models
1993 Standout
Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
1992
An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
1993 Standout
Tissue Plasminogen Activator (rt-PA) vs Heparin in Deep Vein Thrombosis
1990
IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION
1985
The diffusion coefficient of myoglobin in muscle homogenate
1968
The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction
1993
EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION
1986 Standout
ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATOR
1986
TIMI Frame Count
1996 Standout
Development of a Point of Care Lateral Flow Device for Measuring Human Plasma Fibrinogen
2010 StandoutNobel
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
2009 Standout
Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
1991
Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).
1988 Standout
Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
1994 Standout
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
1986
Part 14: Pediatric Advanced Life Support
2010 Standout
Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction
1987
Tissue Plasminogen Activator Reduces Neurological Damage After Cerebral Embolism
1985 Science
Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator
1987
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation
2003
Works of W. Huhmann being referenced
Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Urokinase in Acute Myocardial Infarction: Results of the German Activator Urokinase Study (GAUS)
1988
Untersuchungen �ber die Bedingungen f�r die Sauerstoffversorgung des Myokards an perfundierten Rattenherzen
1967
[Studies on the conditions for the oxygen supply of the myocardium in perfused rat hearts. II. On the function of myoglobin].
1967
RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION
1985